18 November 2019 - BEAM Alliance

BEAM Alliance is releasing a new position paper on PULL Incentives: ‘Incentivising a sustainable response to the threat of AMR’

Without adequate incentives it is anticipated that in less than 2 years from now, many AMR SMEs will have disappeared…

12 April 2019 - BEAM Alliance

BEAM Alliance is proposing a new approach to foster better differentiation between antimicrobials: ‘A new vision for AMR innovation to support medical care’!

By linking a specific ATM to a specific step of the infectious process, novel clinical outcomes could be identified that…

25 March 2019 - BEAM Alliance

BEAM Alliance is releasing a new position paper on PUSH Incentives: ‘Supporting financial investments on R&D to de-risk antimicrobial development!’

The intention of this Memo is to provide different suggestions to help ensure that the R&D funding instruments (e.g. from…

18 November 2019 - BEAM Alliance

New BEAM Alliance Position Paper calls out stakeholders to rapidly provide market-based solutions supporting SME-driven innovation against antimicrobial resistance

The European BEAM Alliance, representing 72 ‘Biotech companies from Europe innovating in AntiMicrobial resistance research’, today released a position paper…

24 August 2020 - Event

4th AMR Conference Novel Antimicrobial & AMR Diagnostics

IMPORTANT UPDATE: Due to the Coronavirus situation, the AMR Conference had to be postponed to 24–25 August in Basel, Switzerland.…

BEAM News
Member News
Events

Latest news of BEAM Alliance

02 April 2020 - BEAM Alliance

Request for Proposals (RFP) for an Agreement for Performance of Work (APW) to develop an online e-learning course on antimicrobial stewardship

To support the Antimicrobial Stewardship and Awareness (ASA) Unit in the Global Coordination and Partnership on Antimicrobial Resistance (GCP) department…

03 December 2019 - BEAM Alliance

New IMI project “COMBINE” launched to accelerate the fight against antimicrobial resistance

The aim of the IMI Antimicrobial Resistance (AMR) Accelerator is to progress the development of new medicines to treat or…

18 November 2019 - BEAM Alliance

BEAM Alliance is releasing a new position paper on PULL Incentives: ‘Incentivising a sustainable response to the threat of AMR’

Without adequate incentives it is anticipated that in less than 2 years from now, many AMR SMEs will have disappeared…

18 November 2019 - BEAM Alliance

New BEAM Alliance Position Paper calls out stakeholders to rapidly provide market-based solutions supporting SME-driven innovation against antimicrobial resistance

The European BEAM Alliance, representing 72 ‘Biotech companies from Europe innovating in AntiMicrobial resistance research’, today released a position paper…

19 July 2019 - BEAM Alliance

BEAM Alliance: Time to give your feedback on how to characterize antimicrobial activity!

The BEAM Alliance proposed a six-way approach to characterize ATM activity, with the aim of opening new doors in the…

06 June 2019 - BEAM Alliance

Emergency on planet AMR: a vital pipeline to protect

The sooner we come up with practical solutions, the more SMEs (and currently developed products) we can save from vanishing.…

page 1/3

Tweets by alliancebeam

View twitter feed

Latest news of BEAM Members

29 May 2020 - Nabriva Therapeutics GmbH

Nabriva Therapeutics Receives Positive EU CHMP Opinion for XENLETA™ (lefamulin) for the Treatment of Community-Acquired Pneumonia (CAP)

XENLETA (lefamulin) is a first-in-class semi-synthetic pleuromutilin antibiotic for systemic administration in humans discovered and developed by the Nabriva Therapeutics…

18 May 2020 - Nabriva Therapeutics GmbH

National Burden of Macrolide-Resistant Streptococcus Pneumoniae in the United States From Blood and Respiratory Tract Cultures Approaches 40 Percent

XENLETA (lefamulin) is a first-in-class semi-synthetic pleuromutilin antibiotic for systemic administration in humans discovered and developed by the Nabriva Therapeutics…

14 May 2020 - Polyphor Ltd

Polyphor announces acceptance of balixafortide abstract at the American Society of Clinical Oncology (ASCO) 2020 virtual scientific program

Polyphor is advancing balixafortide (POL6326) in a Phase III trial in combination with eribulin in patients with advanced breast cancer…

06 May 2020 - ANTABIO S.A.S

Antabio Receives QIDP Designation from the U.S. FDA for the Development of MEM-ANT3310, a Novel Broad-Spectrum Combination Therapy Targeting WHO’s Priority Pathogens

Martin Everett, Chief Scientific Officer of Antabio said: “The receipt of the QIDP designation is an important regulatory milestone for…

05 May 2020 - Nabriva Therapeutics GmbH

XENLETA® (Lefamulin) Treatment Results in a Rapid Time-to-Clinical Response in Hospitalized Patients with Community-Acquired Bacterial Pneumonia (CABP)

XENLETA™ is a first-in-class pleuromutilin antibiotic approved by the U.S. Food and Drug Administration (FDA) for the treatment of community-acquired…

05 May 2020 - BioVersys AG

GARDP signs MOU with Swiss biotech BioVersys AG

Marc Gitzinger, CEO and founder of BioVersys said: “We are delighted to enter into this collaboration with GARDP as it…

page 1/19

Events

07 May 2020

Webinar: Economics Behind the Commercialization of an AMR Product – Understanding the Issues and Fixing it

The goal of this webinar is to provide insight into the economic fundamentals and post marketing commitments, inventory build and…

05 May 2020

Citizen’s engagement & multi stakeholder’s action to tackle antimicrobial resistance and sustain EU progress

ONE health approach MULTIPLE answers: Citizen’s engagement & multi stakeholder’s action to tackle antimicrobial resistance and sustain EU progress

28 April 2020

REVIVE Webinar: Inhaled antimicrobials: Do we get the drug to the bug?

In this webinar, Harm Tiddens will discuss the relation between structural and functional abnormalities of the lung and how this…

28 April 2020

COVID-19 human challenge trials – what will be the regulatory considerations?

The objective of this webinar (45mn presentation / 15mn Q&A) is to explore the potential of CHIM, COVID-19 regulatory considerations,…

26 March 2020

AMR Insights Seminar: Driving Behavioural Change to combat AMR

The Seminar Driving Behavioural Change to combat AMR allows experts from within and outside Europe to give their opinion on…

23 March 2020

BIO-Europe, 14th International Partnering Conference

BIO-Europe Spring 2020 will now be delivered virtually in light of the increasing travel restrictions worldwide due to the ongoing…

22 March 2020

Europe CEO – The Perfect Prelude to Partnering

Europe CEO is an invitation-only, off-the-record forum that brings together the global leaders in the biopharma community to network and…

27 February 2020

REVIVE Webinar: PK/PD murine infection models: Focus on study elements, variability, and interpretation of results

Topics discussed will include: - Understanding and embracing the inherent variability in many components of the murine model. - Demonstrating…

27 February 2020

GARDP webinar: PK/PD murine infection models: Focus on study elements, variability, and interpretation of results

Topics discussed will include: - Understanding and embracing the inherent variability in many components of the murine model - Demonstrating…

page 2/6

Latest news of BEAM Alliance

Request for Proposals (RFP) for an Agreement for Performance of Work (APW) to develop an online e-learning course on antimicrobial stewardship

New IMI project “COMBINE” launched to accelerate the fight against antimicrobial resistance

BEAM Alliance is releasing a new position paper on PULL Incentives: ‘Incentivising a sustainable response to the threat of AMR’

New BEAM Alliance Position Paper calls out stakeholders to rapidly provide market-based solutions supporting SME-driven innovation against antimicrobial resistance

BEAM Alliance: Time to give your feedback on how to characterize antimicrobial activity!

Emergency on planet AMR: a vital pipeline to protect

Latest news of BEAM Members

Nabriva Therapeutics Receives Positive EU CHMP Opinion for XENLETA™ (lefamulin) for the Treatment of Community-Acquired Pneumonia (CAP)

National Burden of Macrolide-Resistant Streptococcus Pneumoniae in the United States From Blood and Respiratory Tract Cultures Approaches 40 Percent

Polyphor announces acceptance of balixafortide abstract at the American Society of Clinical Oncology (ASCO) 2020 virtual scientific program

Antabio Receives QIDP Designation from the U.S. FDA for the Development of MEM-ANT3310, a Novel Broad-Spectrum Combination Therapy Targeting WHO’s Priority Pathogens

XENLETA® (Lefamulin) Treatment Results in a Rapid Time-to-Clinical Response in Hospitalized Patients with Community-Acquired Bacterial Pneumonia (CABP)

GARDP signs MOU with Swiss biotech BioVersys AG

Events

Webinar: Economics Behind the Commercialization of an AMR Product – Understanding the Issues and Fixing it

Citizen’s engagement & multi stakeholder’s action to tackle antimicrobial resistance and sustain EU progress

REVIVE Webinar: Inhaled antimicrobials: Do we get the drug to the bug?

COVID-19 human challenge trials – what will be the regulatory considerations?

AMR Insights Seminar: Driving Behavioural Change to combat AMR

BIO-Europe, 14th International Partnering Conference

Europe CEO – ​The Perfect Prelude to Partnering

REVIVE Webinar: PK/PD murine infection models: Focus on study elements, variability, and interpretation of results

GARDP webinar: PK/PD murine infection models: Focus on study elements, variability, and interpretation of results

Europe CEO – The Perfect Prelude to Partnering